Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ELITE PHARMACEUTICALS INC (ELTP)
|
Add to portfolio |
|
|
|
| Price: |
$0.04
| | Metrics |
| OS: |
1.01
|
B
| |
|
|
| Market cap: |
$38.9
|
M
| |
|
|
|
Net cash:
|
$5.25
|
M
| |
$0.01
|
per share
|
|
EV:
|
$33.7
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$6.0
|
M
| |
5.6
|
x EV/EBITDA
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Mar-31-23 | Mar-31-22 | Mar-31-21 | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 |
| Revenues | 34.2 | 32.3 | 25.4 | 18.0 | 7.6 | 7.5 | 9.6 | 12.5 |
| Revenue growth | 5.9% | 27.1% | 41.0% | 137.8% | 1.5% | -22.6% | -22.9% | 149.2% |
| Cost of goods sold | 17.6 | 17.5 | 13.5 | 10.0 | 4.7 | 3.5 | 5.9 | 4.5 |
| Gross profit | 16.6 | 14.8 | 11.9 | 8.0 | 2.9 | 3.9 | 3.7 | 8.0 |
| Gross margin | 48.6% | 45.9% | 46.8% | 44.3% | 37.9% | 52.9% | 38.8% | 64.1% |
| Research and development | 6.2 | 4.1 | 5.1 | 5.5 | 7.6 | 9.6 | 8.3 | 12.4 |
| General and administrative | 5.1 | 4.5 | 3.3 | 3.3 | 3.1 | 2.3 | 2.1 | 2.9 |
| EBIT | 4.0 | 5.1 | 2.1 | -0.8 | -9.2 | -9.1 | -7.4 | -8.3 |
| EBIT margin | 11.6% | 15.7% | 8.3% | -4.4% | -121.0% | -121.4% | -76.3% | -66.5% |
| Pre-tax income | 4.0 | 6.3 | 4.1 | -2.2 | -10.0 | -4.7 | 1.9 | -1.2 |
| Income taxes | 0.4 | 1.7 | -0.9 | 0.0 | -0.7 | -1.0 | -1.9 | -0.5 |
| Tax rate | 10.6% | 27.5% | | | 6.8% | 22.2% | | 43.2% |
| Earnings from continuing ops | 3.6 | 8.9 | 5.1 | -2.2 | -9.3 | -3.7 | 24.5 | -10.0 |
| Earnings from discontinued ops | | | | 1.1 | | | | |
| Net income | 3.6 | 8.9 | 5.1 | -2.2 | -9.3 | -3.7 | 24.5 | -10.0 |
| Net margin | 10.4% | 27.6% | 20.0% | -12.5% | -122.6% | -49.2% | 254.5% | -79.8% |
| |
| Diluted EPS | $0.00 | $0.01 | $0.01 | $0.00 | ($0.01) | $0.00 | $0.03 | ($0.01) |
| Shares outstanding (diluted) | 1,012.9 | 1,010.6 | 943.0 | 993.3 | 816.3 | 798.2 | 844.5 | 673.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|